{"name":"PrECOG, LLC.","slug":"precog-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Arm A: Belantamab Mafodotin","genericName":"Arm A: Belantamab Mafodotin","slug":"arm-a-belantamab-mafodotin","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"},{"name":"Arm B: Daratumumab Hyaluronidase","genericName":"Arm B: Daratumumab Hyaluronidase","slug":"arm-b-daratumumab-hyaluronidase","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"Induction Venetoclax","genericName":"Induction Venetoclax","slug":"induction-venetoclax","indication":"Chronic lymphocytic leukemia","status":"phase_2"}]}],"pipeline":[{"name":"Arm A: Belantamab Mafodotin","genericName":"Arm A: Belantamab Mafodotin","slug":"arm-a-belantamab-mafodotin","phase":"phase_3","mechanism":"Belantamab mafodotin is an antibody-drug conjugate that targets BCMA on multiple myeloma cells and delivers a cytotoxic payload to kill them.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"Arm B: Daratumumab Hyaluronidase","genericName":"Arm B: Daratumumab Hyaluronidase","slug":"arm-b-daratumumab-hyaluronidase","phase":"phase_3","mechanism":"Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells and triggers their destruction through multiple immune mechanisms, while hyaluronidase enables subcutaneous administration by breaking down hyaluronic acid in subcutaneous tissue.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Induction Venetoclax","genericName":"Induction Venetoclax","slug":"induction-venetoclax","phase":"phase_2","mechanism":"BCL-2 inhibitor","indications":["Chronic lymphocytic leukemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOalJtR2w0aVlVUFlGNlo5bEhmT1RxTmRmcm1FV1l0Z0dCQkVrSVN2aWo3dE1ERTBkR00zbzEwWUtGcjFiM2ZTc3NXeHBsbWZEYlU1Qk9QVXpvT21TMy10NlFiWnhXaTh5NXljeVJvalBmMkNBQXpfZzFUWHNJak1FLXlLZHptaGF2M2plZXQ3NjV3cjZLbmVhM3o1Q01CbXRiZFZQTm83Qlcyam93RnBJOFV4ZG9RU3cwZnJZTUhLejdNakZGbFZN?oc=5","date":"2024-10-01","type":"pipeline","source":"prnewswire.com","summary":"PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - prnewswire.com","headline":"PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}